The FDA has good news for some with CLL. On Oct. 2, 2026, the FDA approved pirtobrutinib as a frontline treatment for CLL / SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma) patients who do not have del(17p). This approval means it can now be used as a first therapy for most patients, not only for those who failed other BTKi treatments.
This approval is encouraging. Pirtobrutinib is taken by mouth once a day, works well, and in studies has generally been easier to tolerate than older chemotherapy, with low rates of some side effects like irregular heartbeat (atrial fibrillation) and high blood pressure. Having another good choice is always a win for patients and their healthcare teams.
What the new studies show:
The approval is based on a head-to-head trial in 282 patients receiving their first CLL treatment. Pirtobrutinib kept CLL under control longer and was better tolerated than the older chemotherapy combination bendamustine plus rituximab (“BR”), with about 93% of people free of worsening disease at 2 years, compared with only about 71% on BR. It also caused fewer serious side effects.
However, one critique of the trial that led to approval is that we already knew BR has no role in CLL today, as a treatment or even as the “comparison” arm in clinical trials. The newer targeted therapies have simply moved past it. Weaker comparators such as BR are still being used in too many trials.
One more important thing to consider: the order of treatments, or “sequencing.”
Pirtobrutinib belongs to a newer class of BTK inhibitors called a “non-covalent” BTK inhibitor. Over time, CLL cells can develop resistance to it. What we are still learning is that with some of these resistance mutations, there is reason to question whether frontline use of pirtobrutinib might also make the older, commonly used BTK inhibitor pills such as zanubrutinib or acalabrutinib ineffective afterward, thereby possibly eliminating future treatment options.
In contrast, we do have good data in the other direction, namely that pirtobrutinib can help many patients who progressed on prior zanubrutinib or acalabrutinib.
The order in which these medicines are used matters, though it is not yet fully worked out. This treatment is an area of active research. Your hematologist/oncologist will help choose the right medicine at the right time for your specific situation, keeping future options open.
The takeaway:
More effective, well-tolerated choices mean more flexibility to personalize your care, and that is great news for people with CLL. The goal is always the same: control the disease, protect quality of life, and keep good options available down the road.
Learn more (official FDA announcement):
You can read the official FDA announcement at FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion.
